The kidney and strategies for the treatment of hypertension.
Renal compensatory mechanisms are a chief consideration when selecting an antihypertensive agent. The relationships, therefore, between renal blood flow and glomerular filtration rate, sodium handling by the kidney, and release of renin require particular attention. We shall examine therapeutic measures such as beta adrenergic blockers, vasodilators, calcium entry blockers, and converting enzyme inhibitors in light of their effects on renal blood flow.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D009248:Nadolol; D009318:Natriuresis / Q000187:drug effects; D011412:Propanolamines / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012079:Renal Circulation / Q000187:drug effects*; D012084:Renin-Angiotensin System / Q000187:drug effects; D013722:Teprotide / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D011412:Propanolamines; D014665:Vasodilator Agents; D009248:Nadolol; D011433:Propranolol; D013722:Teprotide